• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纳米球作为载体:核糖体蛋白 S2 在 PLGA 和壳聚糖纳米球中的新应用,用于治疗急性弓形虫病。

Nanospheres as the delivery vehicle: novel application of ribosomal protein S2 in PLGA and chitosan nanospheres against acute toxoplasmosis.

机构信息

College of animal science and technology, Ningxia University, Yinchuan, Ningxia, China.

Institute of Animal Science, Ningxia Academy of Agricultural and Forestry Science, Yinchuan, China.

出版信息

Front Immunol. 2024 Oct 1;15:1475280. doi: 10.3389/fimmu.2024.1475280. eCollection 2024.

DOI:10.3389/fimmu.2024.1475280
PMID:39416787
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11480959/
Abstract

() is a zoonotic disease that poses great harm to humans and animals. So far, no effective vaccine has been developed to provide fully protection against such parasites. Recently, numerous researches have focused on the use of poly-lactic-co-glycolic acid (PLGA) and chitosan (CS) for the vaccines against infections. In this study, we employed PLGA and CS as the vehicles for ribosome protein (TgRPS2) delivery. TgRPS2-PLGA and TgRPS2-CS nanospheres were synthesized by double emulsion solvent evaporation and ionic gelation technique as the nano vaccines. Before immunization in animals, the release efficacy and toxicity of the synthesized nanospheres were evaluated . Then, ICR mice were immunized intramuscularly, and immune protections of the synthesized nanospheres were assessed. The results showed that TgRPS2-PLGA and TgRPS2-CS nanospheres could induce higher levels of IgG and cytokines, activate dendritic cells, and promote the expression of histocompatibility complexes. The splenic lymphocyte proliferation and the enhancement in the proportion of CD4 and CD8 T lymphocytes were also observed in immunized animals. In addition, two types of nanospheres could significantly inhabit the replications of in cardiac muscles and spleen tissues. All these obtained results in this study demonstrated that the TgRPS2 protein delivered by PLGA or CS nanospheres provided satisfactory immunoprotective effects in resisting , and such formulations illustrated potential as prospective preventive agents for toxoplasmosis.

摘要

刚地弓形虫病是一种人畜共患疾病,对人类和动物都有很大的危害。到目前为止,还没有开发出有效的疫苗来提供对这种寄生虫的完全保护。最近,许多研究都集中在使用聚乳酸-羟基乙酸共聚物(PLGA)和壳聚糖(CS)作为弓形虫病疫苗上。在本研究中,我们将 PLGA 和 CS 用作核糖体蛋白(TgRPS2)的载体。通过双乳液溶剂蒸发和离子凝胶技术合成了 TgRPS2-PLGA 和 TgRPS2-CS 纳米球,作为纳米疫苗。在动物免疫之前,评估了合成纳米球的释放效果和毒性。然后,通过肌肉内免疫 ICR 小鼠,并评估了合成纳米球的免疫保护效果。结果表明,TgRPS2-PLGA 和 TgRPS2-CS 纳米球可以诱导更高水平的 IgG 和细胞因子,激活树突状细胞,并促进组织相容性复合物的表达。免疫动物的脾淋巴细胞增殖和 CD4 和 CD8 T 淋巴细胞比例增加也得到了观察。此外,两种类型的纳米球都可以显著抑制弓形虫在心肌和脾脏组织中的复制。本研究的所有结果表明,PLGA 或 CS 纳米球递送的 TgRPS2 蛋白在抵抗弓形虫病方面提供了令人满意的免疫保护效果,并且这些制剂显示出作为弓形虫病预防剂的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/f9cb5ab7bd2d/fimmu-15-1475280-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/bc0195a59394/fimmu-15-1475280-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/c0e3794b8f68/fimmu-15-1475280-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/838255fce00b/fimmu-15-1475280-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/32b332c66fc3/fimmu-15-1475280-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/34ad0345c75f/fimmu-15-1475280-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/b26d12d51476/fimmu-15-1475280-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/b4c458a5f909/fimmu-15-1475280-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/34c984e29141/fimmu-15-1475280-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/f0def728ae80/fimmu-15-1475280-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/663f0d8ad062/fimmu-15-1475280-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/69e354a890d0/fimmu-15-1475280-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/f9cb5ab7bd2d/fimmu-15-1475280-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/bc0195a59394/fimmu-15-1475280-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/c0e3794b8f68/fimmu-15-1475280-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/838255fce00b/fimmu-15-1475280-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/32b332c66fc3/fimmu-15-1475280-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/34ad0345c75f/fimmu-15-1475280-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/b26d12d51476/fimmu-15-1475280-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/b4c458a5f909/fimmu-15-1475280-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/34c984e29141/fimmu-15-1475280-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/f0def728ae80/fimmu-15-1475280-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/663f0d8ad062/fimmu-15-1475280-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/69e354a890d0/fimmu-15-1475280-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6847/11480959/f9cb5ab7bd2d/fimmu-15-1475280-g012.jpg

相似文献

1
Nanospheres as the delivery vehicle: novel application of ribosomal protein S2 in PLGA and chitosan nanospheres against acute toxoplasmosis.纳米球作为载体:核糖体蛋白 S2 在 PLGA 和壳聚糖纳米球中的新应用,用于治疗急性弓形虫病。
Front Immunol. 2024 Oct 1;15:1475280. doi: 10.3389/fimmu.2024.1475280. eCollection 2024.
2
With Chitosan and PLGA as the Delivery Vehicle, Oxidoreductase-Based DNA Vaccines Decrease Parasite Burdens in Mice.壳聚糖和 PLGA 作为递药载体,基于氧化还原酶的 DNA 疫苗降低了小鼠体内寄生虫负荷。
Front Immunol. 2021 Aug 27;12:726615. doi: 10.3389/fimmu.2021.726615. eCollection 2021.
3
Nano vaccines for Ribosomal P2 Protein With Nanomaterials as a Promising DNA Vaccine Against Toxoplasmosis.纳米疫苗针对核糖体 P2 蛋白,纳米材料作为弓形虫有希望的 DNA 疫苗。
Front Immunol. 2022 Feb 21;13:839489. doi: 10.3389/fimmu.2022.839489. eCollection 2022.
4
Construction of Toxoplasma gondii SRS29C nucleic acid vaccine and comparative immunoprotective study of an SRS29C and SAG1 combination.弓形虫 SRS29C 核酸疫苗的构建及 SRS29C 与 SAG1 联合的免疫保护性比较研究。
Mol Biochem Parasitol. 2024 Sep;259:111630. doi: 10.1016/j.molbiopara.2024.111630. Epub 2024 May 23.
5
Nano DNA Vaccine Encoding Histone Deacetylase SIR2 Enhanced Protective Immunity in Mice.编码组蛋白去乙酰化酶SIR2的纳米DNA疫苗增强小鼠的保护性免疫。
Pharmaceutics. 2021 Sep 29;13(10):1582. doi: 10.3390/pharmaceutics13101582.
6
Evaluation of protective immunity induced by DNA vaccination with genes encoding Toxoplasma gondii GRA17 and GRA23 against acute toxoplasmosis in mice.用编码刚地弓形虫GRA17和GRA23的基因进行DNA疫苗接种诱导的保护性免疫对小鼠急性弓形虫病的评估。
Exp Parasitol. 2017 Aug;179:20-27. doi: 10.1016/j.exppara.2017.06.002. Epub 2017 Jun 15.
7
Protective effect of a DNA vaccine cocktail encoding ROP13 and GRA14 with Alum nano-adjuvant against Toxoplasma gondii infection in mice.用含有纳米佐剂的 ROP13 和 GRA14 基因 DNA 疫苗鸡尾酒对小鼠弓形虫感染的保护作用。
Int J Biochem Cell Biol. 2021 Mar;132:105920. doi: 10.1016/j.biocel.2021.105920. Epub 2021 Jan 7.
8
Vaccination with Toxoplasma gondii calcium-dependent protein kinase 6 and rhoptry protein 18 encapsulated in poly(lactide-co-glycolide) microspheres induces long-term protective immunity in mice.用封装在聚(丙交酯-共-乙交酯)微球中的弓形虫钙依赖性蛋白激酶6和棒状体蛋白18进行疫苗接种可诱导小鼠产生长期保护性免疫。
BMC Infect Dis. 2016 Apr 18;16:168. doi: 10.1186/s12879-016-1496-0.
9
Synergistic effect of rSAG1 and rGRA2 antigens formulated in PLGA microspheres in eliciting immune protection against Toxoplasama gondii.聚乳酸-羟基乙酸共聚物(PLGA)微球包裹的重组抗原rSAG1和rGRA2联合免疫对弓形虫感染的协同免疫保护作用
Exp Parasitol. 2016 Nov;170:236-246. doi: 10.1016/j.exppara.2016.09.008. Epub 2016 Sep 20.
10
Chitosan Microsphere Used as an Effective System to Deliver a Linked Antigenic Peptides Vaccine Protect Mice Against Acute and Chronic .壳聚糖微球作为一种有效的递呈偶联抗原肽疫苗系统对急性和慢性 感染的保护作用
Front Cell Infect Microbiol. 2018 May 23;8:163. doi: 10.3389/fcimb.2018.00163. eCollection 2018.

本文引用的文献

1
Oral administration of recombinant outer membrane protein A-based nanovaccine affords protection against Aeromonas hydrophila in zebrafish.口服重组外膜蛋白 A 纳米疫苗可预防斑马鱼感染嗜水气单胞菌。
World J Microbiol Biotechnol. 2024 Jun 24;40(8):250. doi: 10.1007/s11274-024-04059-y.
2
Sustained release system from PLGA particles co-encapsulated with inactivated influenza virus with natural killer T cell agonist α-galactosylceramide.载有甲型流感病毒和自然杀伤 T 细胞激动剂 α-半乳糖神经酰胺的 PLGA 颗粒的控释系统。
Eur J Pharm Biopharm. 2024 Aug;201:114365. doi: 10.1016/j.ejpb.2024.114365. Epub 2024 Jun 12.
3
Protective efficacy of Eimeria maxima EmLPL and EmTregIM-1 against homologous challenge in chickens.
柔嫩艾美耳球虫 EmLPL 和 EmTregIM-1 对鸡同源攻毒的保护效力。
Poult Sci. 2024 Jul;103(7):103865. doi: 10.1016/j.psj.2024.103865. Epub 2024 May 16.
4
Alginate-Based Encapsulation Fabrication Technique for Drug Delivery: An Updated Review of Particle Type, Formulation Technique, Pharmaceutical Ingredient, and Targeted Delivery System.用于药物递送的基于海藻酸盐的包封制备技术:颗粒类型、制剂技术、药物成分和靶向递送系统的最新综述
Pharmaceutics. 2024 Mar 6;16(3):370. doi: 10.3390/pharmaceutics16030370.
5
Immunomodulatory chitosan nanoparticles for Toxoplasma gondii infection: Novel application of chitosan in complex propranolol-hydrochloride as an adjuvant in vaccine delivery.免疫调节壳聚糖纳米颗粒治疗弓形虫感染:壳聚糖在复杂盐酸普萘洛尔中的新应用作为疫苗传递佐剂。
Int J Biol Macromol. 2023 Dec 31;253(Pt 8):127228. doi: 10.1016/j.ijbiomac.2023.127228. Epub 2023 Oct 14.
6
Recent progress in application of nanovaccines for enhancing mucosal immune responses.纳米疫苗在增强黏膜免疫反应应用方面的最新进展。
Acta Pharm Sin B. 2023 Jun;13(6):2334-2345. doi: 10.1016/j.apsb.2022.08.010. Epub 2022 Aug 21.
7
infection: novel emerging therapeutic targets.感染:新出现的治疗靶点。
Expert Opin Ther Targets. 2023 Apr-May;27(4-5):293-304. doi: 10.1080/14728222.2023.2217353. Epub 2023 May 24.
8
Nanoparticles as a Delivery System of Antigens for the Development of an Effective Vaccine against .纳米颗粒作为抗原递送系统用于开发针对……的有效疫苗
Vaccines (Basel). 2023 Mar 25;11(4):733. doi: 10.3390/vaccines11040733.
9
A novel TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice.一种新型的TGGT1_316290 mRNA-LNP疫苗在小鼠中引发针对弓形虫病的保护性免疫反应。
Front Microbiol. 2023 Mar 21;14:1145114. doi: 10.3389/fmicb.2023.1145114. eCollection 2023.
10
Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines.基于蛋白质的 SARS-CoV-2 纳米疫苗:候选疫苗的当前设计策略和进展。
Int J Biol Macromol. 2023 May 1;236:123979. doi: 10.1016/j.ijbiomac.2023.123979. Epub 2023 Mar 10.